Slide 1: Making life easier
Conference call presentation 9M 2020/21 Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP ‘I love taking my boat out and I do so whenever I can. Sometimes the weather stops me. But I won’t let my condition stop me.’ Flemming Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Car
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Q3 organic growth of 11% and EBIT margin of 33% – financial guidance narrowed
Q3 organic growth of 11% and EBIT margin of 33% – financial guidance for FY 2020/21 narrowed REVENUE GROWTH Q3 Highlights Reported revenue (mDKK) +3% • Organic growth of 11% and 9% reported growth in DKK Organic growth • Organic growth rates by business area: Ostomy Care 4%, Continence Care 5%, +6%
Slide 4: We have made significant progress across the Clinical Performance Program
We have made significant progress across the Clinical Performance Program Status October 2020 Status June 2021 Expected launch Product launch Digital ostomy - CE mark has been granted expected in first solution Pilot studies conducted with successful results ✓ - Payer pilot studies in Germany and th
Slide 5: Q3 growth driven by Interventional Urology recovery led by Men's Health
Q3 growth was driven by a recovery in Interventional Urology led by Men’s Health and improving underlying growth in Europe Q3 20/21 revenue by business area Q3 20/21 revenue by geography Business Reported revenue Q3 Organic growth Organic growth Geographic Reported revenue Q3 Organic growth Organic
Slide 6: 9M 2020/21 reported revenue was up 3%, impacted by currency depreciation
9M 2020/21 reported revenue was up 3%, impacted by depreciation in the USD, GBP and Emerging market currencies 9M Revenue development (DKKm) Highlights • 9M 2020/21 reported revenue increased by DKK 372 million compared to 9M 2019/20 840 12 -481 • 9M organic growth was 6% or DKK 840 million 14,326 •
Slide 7: 9M 2020/21 reported EBIT margin of 33% driven by efficiency gains
9M 2020/21 reported EBIT margin of 33% driven by efficiency gains and lower commercial spending due to COVID-19 9M EBIT margin development (%) Highlights • 9M gross margin was 68%, on par with last year 33.4 • Positive impact from leverage on production costs and 0.3 0.0 0.1 32.8 efficiency gains fr
Slide 8: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings FCF development Comments Highlights • Free cash flow for 9M 2020/21 was DKK 1,626 million compared to DKK 2,436 million in 9M 2019/20 98 99 98 93 • Adjusting for acquisitions, mainly Nine Continents Medical, the free 90 91 cash flow for 9M 2020/
Slide 9: Organic growth guidance for FY 2020/21 narrowed
Organic growth guidance for FY 2020/21 narrowed GUIDANCE 2020/21 GUIDANCE 2020/21 (DKK)* KEY ASSUMPTIONS • Double-digit growth in the second half of 2020/21 SALES Lower end of 7-8% Unchanged 4-5% • Continued resumption of elective procedures and hospital activity across business range range areas as
Slide 10: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /